Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with aids

Seth L. Newman, Timothy P. Flanigan, Alvan Fisher, Michael G. Rinaldi, Michael Stein, Kevin Vigilante

Research output: Contribution to journalArticlepeer-review

111 Scopus citations

Abstract

Eight cases of severe mucosal candidiasis in patients with AIDS who were taking fluconazole at a dosage of 400-800 mg/d are described. Candida albicans alone or in conjunction with Torulopsis glabrata or Candida stellatoidea was isolated from each patient. In vitro susceptibility testing demonstrated resistance to fluconazole in all eight cases. All tested isolates were susceptible to amphotericin B, and six of eight isolates tested were susceptible to itraconazole. All individuals were severely immunocompromised (CD4 lymphocyte counts: mean, 15/mm3; range, 6-39/mm3) and had been receiving prophylaxis with fluconazole for a mean of only 3 months (range, 1-7 months). The occurrence of candida! mucositis in patients receiving high doses of fluconazole is a matter of concernthat requires further study in regard to the causes, prevention, and treatment of the disease.

Original languageEnglish (US)
Pages (from-to)684-686
Number of pages3
JournalClinical Infectious Diseases
Volume19
Issue number4
DOIs
StatePublished - Oct 1994
Externally publishedYes

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with aids'. Together they form a unique fingerprint.

Cite this